A61K 40/17
Monocytes
Official title: Monocytes; Macrophages
A61K40/17 (Monocytes) appears on 213 US grants and 494 published applications in this corpus.
Search patents in A61K- Granted patents
- 213
- Published applications
- 494
- Assignees
- 273
- Inventors
- 1,043
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 5 | 0 |
| 2001 | 3 | 2 |
| 2002 | 16 | 11 |
| 2003 | 4 | 4 |
| 2004 | 6 | 9 |
| 2005 | 1 | 9 |
| 2006 | 0 | 6 |
| 2007 | 1 | 4 |
| 2008 | 1 | 2 |
| 2009 | 2 | 9 |
| 2010 | 3 | 6 |
| 2011 | 2 | 7 |
| 2012 | 2 | 7 |
| 2013 | 7 | 10 |
| 2014 | 12 | 12 |
| 2015 | 7 | 11 |
| 2016 | 11 | 8 |
| 2017 | 5 | 14 |
| 2018 | 2 | 22 |
| 2019 | 6 | 20 |
| 2020 | 6 | 35 |
| 2021 | 15 | 35 |
| 2022 | 19 | 54 |
| 2023 | 19 | 42 |
| 2024 | 14 | 62 |
| 2025 | 21 | 47 |
| 2026 | 13 | 46 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- Compositions and methods for treating cancer6 Oct 2026US 12,753,236 B2Alpha Beta Holdings, LLC
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof11 Aug 2026US 12,702,681 B2Shanghai RoyalTech Med CO., Ltd
- Cancer antigens and methods14 Jul 2026US 12,680,105 B2Enara Bio Limited
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Modulation of b-cell translocation gene 1 (btg1) for use in adoptive cell therapy1 Oct 2026US 2026/0294968 A1Baylor College of Medicine
- Patrolling monocyte cellular therapy1 Oct 2026US 2026/0297525 A1New York Blood Center, Inc.
- SIRPalpha Knockout iPSC-derived and CAR-comprising Macrophages with Enhanced Anti-tumor Activity24 Sep 2026US 2026/0284104 A1Wisconsin Alumni Research Foundation
- Antigen binding protein targeting cd39 and use thereof24 Sep 2026US 2026/0286002 A1Oricell Therapeutics Co., Ltd.
Most cited
By later US patents
- Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy109US 5,830,464 AFordham University · 1998
- Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes92US 5,985,270 AFordham University · 1999
- Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes64US 6,017,540 AFordham University · 2000
- Ocular therapy with homologous macrophages57US 5,676,944 AThe Regents of the University of California · 1997
- Treatment of primary and metastatic neoplastic diseases with HSP70-peptide complexes57US 6,403,095 B1Fordham University · 2002